Investing.com - Amoy Diagnostics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Amoy Diagnostics announced earnings per share of ¥0.35 on revenue of ¥206.80. Analysts polled by Investing.com anticipated EPS of ¥0.20 on revenue of ¥282.55M.
Amoy Diagnostics shares are up 50% from the beginning of the year, still down 54.65% from its 52 week high of ¥48.88 set on November 29, 2021.
Amoy Diagnostics shares lost 11.50% in intra-day trade following the report.
Amoy Diagnostics follows other major Healthcare sector earnings this month
Amoy Diagnostics's report follows an earnings missed by Walvax BioTech on Tuesday, who reported EPS of ¥0.07 on revenue of ¥1.36B, compared to forecasts EPS of ¥0.18 on revenue of ¥1.55B.
Top Choice Medical Investment had missed expectations on Tuesday with third quarter EPS of ¥0.68 on revenue of ¥821.2M, compared to forecast for EPS of ¥0.95 on revenue of ¥1.08B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar